Clinical characteristics of patients with B cell malignancy
| Patient no. | Malignancy | Age (years) | Sex | Chemotherapy regimens | Bone marrow involvement | Total. of CAR-T cells infused (×106) | Response | Mutation |
| 1 | HGBCL | 24 | Female | R-CHOP+Hyper CVAD A and B | Yes | 21.8 | Relapse | p.163. R-L |
| 2 | MCL | 54 | Male | CHOP+DHAP | Yes | 32.2 | CR | No |
| 3 | DLBLC | 54 | Male | R-CHOP+R-ECHOP | Yes* | 105 | NR | p.174. L-V |
| 4 | DLBLC | 47 | Female | R-CHOP | No | 35.5 | NR | p.174. L-V |
*The bone marrow involvement was occurred on day 37 after CAR-T cells infusion.
CAR, chimeric antigen receptor; DLBLC, diffuse large B cell lymphoma; HGBCL, high grade B cell lymphoma; MCL, mantle cell lymphoma.